ArticleNPJ precision oncology2025
Longitudinal investigation of albumin-to-globulin ratio for human cancers demonstrates benefit in postoperative serial remeasurement.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pretransplant albumin-to-globulin ratio and long-term outcomes after liver transplantation for hepatocellular carcinoma: a two-center cohort study.Frontiers in oncology · 2026Article
- Dynamic survival prediction using longitudinal AGR in unresectable locally advanced esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Previous studies on serum albumin-to-globulin ratio (AGR) in human cancers were limited to its preoperative level, with postoperative serial AGR remeasurements ignored. In this study, 2844 CRC patients, 2267 NSCLC patients and 507 HCC patients who underwent curative resection were included. Postoperative AGR was a prognostic factor independent to preoperative AGR, performing a L shaped relation with OS. The 5-year OS rates for the persistently normal, normalized, lowered and persistently low perioperative AGR groups were 84.0%, 80.7%, 78.5% and 70.2%. Three longitudinal AGR trajectory groups were identified within 12 months after surgery. Compared with the normal-stable group, the adjusted HRs on OS for the rising-decreasing and decreasing-rising groups were 1.38 (95% CI: 1.13-1.68, P = 0.001) and 2.78 (95% CI: 2.30-3.36, P < 0.001). Similar results were observed for RFS. In conclusion, a routine follow-up of AGR in the postoperative surveillance will improve prognosis risk stratification of cancer patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.